Changes in mononuclear cell subsets in capillary and venous blood of patients with psoriasis depending on the treatment

Topical glucocorticoids are conventionally used to treat psoriasis, but such treatment provides a short-term effect, and may cause various complications during long-term usage. A detailed study of the immunopathogenesis psoriasis has made it possible use bioengineered drugs that block main cytokines. It been shown IL-36 plays an important regulatory role in pathogenesis psoriasis. The aim was therapeutic effect patients with using topical glucocorticoid hormone versus IL- 36 receptor antagonist (RAIL-36), respect clinical course subsets mononuclear cells venous capillary blood taken close focus inflammation. 16 (group 1a) received 0.1% mometasone cream for 14 days; 20 group 1b gel containing 0.4% recombinant RAIL-36 days. Control included healthy adults. Treatment efficacy assessed by PASI, DISHS DLQI indices. 19 lymphocyte 3 monocyte were four-color staining whole erythrocyte lysis BD Biosciences (USA) technologies reagents. both led decrease severity disease at end treatment. However, 2 weeks after 1a, indexes nearly returned initial values. Meanwhile, reduced index levels persisted later 1b. Significant deviations (more pronounced blood) revealed several leukocyte compared persons. As result treatment, we have some changes common two groups, special differences options, more samples. Both medical preparations suitable